<DOC>
	<DOCNO>NCT00741013</DOCNO>
	<brief_summary>In randomize , double-blind , placebo control trial use positron emission tomography determine lovastatin recombinant human activate protein C exhibit anti-inflammatory effect human follow intrabronchial installation lipopolysaccharide ( LPS endotoxin ) .</brief_summary>
	<brief_title>Quantifying Airway Inflammation With Radiologic Tests</brief_title>
	<detailed_description>Quantitative , noninvasive biomarkers lung-specific inflammation yet develop potentially contribute significantly development therapy treat lung inflammation . The purpose study demonstrate positron emission tomographic ( PET ) image [ 18F } fluorodeoxyglucose ( FDG-PET ) use quantify change lung inflammation healthy volunteer .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<criteria>Healthy , man woman , race ethnicity , age 19 44 year old Screening FEV1 FVC must &gt; 80 % predict . Screening oxygen saturation pulse oximetry &gt; 97 % room air . Research volunteer must capable lie still supine within PET scanner ~2 Â½ hour . Research volunteer must capable fast 6 hour . Pregnancy ( confirm qualitative urine hCG pregnancy test ) Lactation . Actively menstruating time randomization History tobacco use smoke illicit drug ( marijuana , cocaine ) past year . Research volunteer currently take prescription medication . Research volunteer increase risk radiation exposure ( e.g . flight attendant ) Research volunteer enrol another research study investigational drug . Research volunteer know allergy trimethoprim/sulfamethoxazole amoxicillin . Research volunteer know allergy drug routinely use bronchoscopy . Research volunteer know allergy lovastatin rhAPC Fasting glucose time PET study &gt; 150 mg/dl . Exclusion criterion relate use rhAPC : Active history internal bleeding within past 3 month History hemorrhagic stroke within past 3 month . History intracranial intraspinal surgery , severe head trauma , within past 3 month History trauma increase risk lifethreatening bleed within past 3 month History receive thrombolytic therapy within past 3 month . History receive oral anticoagulant glycoprotein IIb/IIIa inhibitor within past 3 month . History use aspirin &gt; 650 mg/d platelet inhibitor within past 7 day . Any history intracranial arteriovenous malformation aneurysm Any history know bleed diathesis Any history chronic severe hepatic disease Presence epidural catheter Any history intracranial neoplasm mass lesion evidence cerebral herniation Use heparin past 7 day Platelet count &lt; 100,000 x 106/L Prothrombin timeINR &gt; 1.5 SGOT &gt; 47 IU/L , SGPT &gt; 53 IU/L , bilirubin &gt; 1.1 mg/dl Any condition bleeding constitute significant hazard would particularly difficult manage location . Exclusion criterion relate use lovastatin : History chronic active liver disease acute liver disease within past 3 month SGOT &gt; 47 IU/L , SGPT &gt; 53 IU/L , bilirubin &gt; 1.1 mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>randomize</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>lung inflammation</keyword>
	<keyword>lovastatin</keyword>
	<keyword>recombinant human activate protein C</keyword>
	<keyword>endotoxin</keyword>
	<keyword>fluorodeoxyglucose</keyword>
</DOC>